2021
Admission computed tomography radiomic signatures outperform hematoma volume in predicting baseline clinical severity and functional outcome in the ATACH‐2 trial intracerebral hemorrhage population
Haider SP, Qureshi AI, Jain A, Tharmaseelan H, Berson ER, Zeevi T, Majidi S, Filippi CG, Iseke S, Gross M, Acosta JN, Malhotra A, Kim JA, Sansing LH, Falcone GJ, Sheth KN, Payabvash S. Admission computed tomography radiomic signatures outperform hematoma volume in predicting baseline clinical severity and functional outcome in the ATACH‐2 trial intracerebral hemorrhage population. European Journal Of Neurology 2021, 28: 2989-3000. PMID: 34189814, PMCID: PMC8818333, DOI: 10.1111/ene.15000.Peer-Reviewed Original ResearchConceptsAdmission Glasgow Coma ScaleGlasgow Coma ScaleRadiomics signatureMRS scoreHematoma volumeICH volumeClinical severityNoncontrast head CT scansAdmission National InstitutesHealth Stroke ScaleRankin Scale scoreStrong associationBaseline clinical severityMedium-term outcomesIndependent validation cohortHead CT scanATACH-2 trialStroke ScaleAdmission NIHSSIndependent predictorsClinical presentationComa ScaleBaseline CTICH patientsValidation cohort
2019
Antiplatelet Therapy After Spontaneous Intracerebral Hemorrhage and Functional Outcomes
Murthy SB, Biffi A, Falcone GJ, Sansing LH, Torres Lopez V, Navi BB, Roh DJ, Mandava P, Hanley DF, Ziai WC, Kamel H, Rosand J, Sheth KN, Butcher K, Davis S, Gregson B, Lees K, Lyden P, Mayer S, Muir K, Steiner T. Antiplatelet Therapy After Spontaneous Intracerebral Hemorrhage and Functional Outcomes. Stroke 2019, 50: 3057-3063. PMID: 31895618, PMCID: PMC6941441, DOI: 10.1161/strokeaha.119.025972.Peer-Reviewed Original ResearchConceptsAntiplatelet therapyIntracerebral hemorrhageFunctional outcomeHematoma locationCause mortalityMajor disabilityVirtual International Stroke Trials Archive databaseCox proportional regression analysisConclusions Antiplatelet therapyRecurrent intracerebral hemorrhageProportional regression analysisPoor functional outcomeRandomized clinical trialsSpontaneous intracerebral hemorrhagePaucity of dataAntiplatelet medicationsStroke RegistryThromboembolic riskHazard ratioMulticenter cohortPrimary outcomeMedian timeICH patientsClinical trialsMeta-analyzed data
2013
β-Blockers associated with no class-specific survival benefit in acute intracerebral hemorrhage
Shoup JP, Winkler J, Czap A, Staff I, Fortunato G, McCullough LD, Sansing LH. β-Blockers associated with no class-specific survival benefit in acute intracerebral hemorrhage. Journal Of The Neurological Sciences 2013, 336: 127-131. PMID: 24183854, PMCID: PMC4956481, DOI: 10.1016/j.jns.2013.10.022.Peer-Reviewed Original ResearchConceptsΒ-blocker treatmentΒ-blocker useBlood pressure controlAcute intracerebral hemorrhageIntracerebral hemorrhageAdrenergic antagonistsAntihypertensive therapyPressure controlInflammation-induced injuryΒ-blocker therapyDatabase of patientsSympathetic nervous systemSpontaneous intracerebral hemorrhageAntihypertensive treatmentInpatient deathSurvival benefitImproved survivalOngoing trialsMultivariable analysisICH patientsImmune activationInpatient stayRetrospective analysisStudy populationΒ-blockers